Sanctions Risk Associated with U.S. Anti-Kickback Statute and FCPA Violations
First written in FY2016. 1 of 2 entries say "Materialised", first in FY2016. Latest entry: FY2018.
The whole theme swung hardest in 2021: 1 of 6 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2018RestatedAnnual report
「The company's overseas subsidiary agreed in February 2016 to enter into an agreement with the U.S. Department of Justice regarding deferred prosecution in connection with suspected violations of the U.S. Anti-Kickback Statute, the U.S. False Claims Act and the FCPA relating to past healthcare business activities.」
Reiterated the past matters concerning the U.S. Anti-Kickback Statute, the False Claims Act and the FCPA, as well as the deferred prosecution agreement. - FY2016MaterialisedAnnual report
「The company's overseas subsidiary agreed in February 2016 to enter into an agreement with the U.S. Department of Justice regarding deferred prosecution in connection with suspected violations of the U.S. Anti-Kickback Statute, the U.S. False Claims Act and the FCPA relating to past healthcare business activities.」
In connection with the agreement with the U.S. Department of Justice, the company recorded ¥18.814 billion in losses related to the U.S. Anti-Kickback Statute and other matters during the period.